Sibel Health Powers Digital Health Future with $39M Funding, New Leadership
October 16, 2025, 3:39 pm
Location: United States, Illinois, Chicago
Employees: 10001+
Founded date: 1972
Location: United States, California, Mountain View
Employees: 51-200
Founded date: 2013
Sibel Health secured a Series C extension, bringing total funding to $39 million. Maruho and Samsung Next notably invested. This capital drives Sibel's core digital health platform, ANNE One. ANNE One is an FDA-cleared clinical monitoring system. The company also bolstered its leadership. Kimberly Querrey assumed the Chairwoman role. Tim Sullivan joined the board as an independent member. Sibel Health aims for transformative patient care. It champions continuous monitoring and predictive insights. The firm targets dermatology and remote clinical trials. It leverages advanced medical wearables integrated with mobile technology. This marks a new era in accessible, smart healthcare.
Sibel Health, a leader in digital health innovation, significantly boosted its financial standing. The company completed a Series C extension financing round. This latest capital infusion brings its total Series C funding to $39 million. The move solidifies Sibel Health's position in the evolving healthcare technology landscape. It signals strong investor confidence in its vision and products.
This recent extension attracted powerful strategic investors. Maruho, a key player in Asia's dermatological products market, joined the round. Samsung Next, known for its global technology and innovation ecosystem, also invested. These new partners bring vital industry expertise and market reach. They complement the initial Series C round, which secured funding from The Steele Foundation for Hope and Dräger.
Sibel Health's cornerstone product is ANNE One. This FDA-cleared clinical monitoring platform is central to its offerings. ANNE One leverages advanced wearable sensors. It integrates AI-enabled data analytics. The platform features an integrated mobile software and cloud system. Samsung mobile devices display waveforms and provide alerts. This integration enhances usability and demonstrates strong technological synergy. The ANNE One system delivers continuous, real-world health data. It transitions care from episodic to predictive.
Beyond ANNE One, Sibel Health operates its Discovery platform. This platform serves pharmaceutical companies. It facilitates continuous data collection in home settings. This capability is crucial for modern clinical trials. It offers a more comprehensive view of patient health. The Discovery platform supports decentralized trial models. It improves efficiency and data quality for drug development.
The partnership with Maruho is strategically vital. Maruho specializes in dermatological solutions. Its investment deepens an existing commercial collaboration. This joint effort focuses on innovative therapeutic digital health technologies. These are specifically designed for dermatology. The aim is to enhance treatment effectiveness. It also seeks to improve accessibility for skin-related conditions. This alliance promises significant advancements in a critical healthcare area.
Samsung Next's investment reinforces technological integration. Sibel Health's ANNE One already uses Samsung mobile devices. This collaboration highlights the potential for future innovations. It creates a differentiated product for healthcare providers. Life science companies also benefit. The system offers clinically validated solutions. It maintains cost-effectiveness. The combined forces aim to expand the reach and impact of medical wearables.
Sibel Health also strengthened its leadership team. Two significant board appointments guide its next growth phase. Kimberly Querrey now serves as Chairwoman of the board. Querrey brings extensive experience. She is Chair and CEO of Gulf Shore Private Capital, LLC. She has been involved with Sibel Health since its 2018 inception. Querrey also serves as a Trustee of Northwestern University. Her leadership provides deep insights into corporate governance and strategic development.
Tim Sullivan joined as a new independent board member. Sullivan is a Co-Founder and Vice Chair of Madison Dearborn Partners. He also chairs the Board of Northwestern Memorial Healthcare Corporation. His background covers innovation, healthcare, and commercial acceleration. Sullivan's expertise will prove invaluable. It will guide Sibel Health's continued expansion and impact. His appointment adds significant strategic depth to the board.
Sibel Health's vision centers on improving patient care. It achieves this through leading-edge technology. Strategic partnerships drive its mission. The company aims to seamlessly integrate continuous health data. This data feeds into clinical trials and everyday clinical care. This transition from reactive monitoring to predictive clinical intelligence is paramount. It allows for proactive interventions.
The company understands care extends beyond hospital walls. Its solutions support this shift. Continuous monitoring enables remote patient management. It provides valuable insights outside traditional healthcare settings. This approach makes healthcare more accessible. It empowers patients and providers alike. Sibel Health champions a future of connected, intelligent health.
Sibel Health maintains its headquarters in Chicago, IL. It also operates an international office in Seoul. This dual presence underscores its global ambitions. The company is poised for significant advancements. Its robust funding, strategic alliances, and strengthened leadership pave the way. Sibel Health continues to define the future of digital health. It drives innovation in medical wearables and AI-driven health analytics.
Sibel Health, a leader in digital health innovation, significantly boosted its financial standing. The company completed a Series C extension financing round. This latest capital infusion brings its total Series C funding to $39 million. The move solidifies Sibel Health's position in the evolving healthcare technology landscape. It signals strong investor confidence in its vision and products.
This recent extension attracted powerful strategic investors. Maruho, a key player in Asia's dermatological products market, joined the round. Samsung Next, known for its global technology and innovation ecosystem, also invested. These new partners bring vital industry expertise and market reach. They complement the initial Series C round, which secured funding from The Steele Foundation for Hope and Dräger.
Sibel Health's cornerstone product is ANNE One. This FDA-cleared clinical monitoring platform is central to its offerings. ANNE One leverages advanced wearable sensors. It integrates AI-enabled data analytics. The platform features an integrated mobile software and cloud system. Samsung mobile devices display waveforms and provide alerts. This integration enhances usability and demonstrates strong technological synergy. The ANNE One system delivers continuous, real-world health data. It transitions care from episodic to predictive.
Beyond ANNE One, Sibel Health operates its Discovery platform. This platform serves pharmaceutical companies. It facilitates continuous data collection in home settings. This capability is crucial for modern clinical trials. It offers a more comprehensive view of patient health. The Discovery platform supports decentralized trial models. It improves efficiency and data quality for drug development.
The partnership with Maruho is strategically vital. Maruho specializes in dermatological solutions. Its investment deepens an existing commercial collaboration. This joint effort focuses on innovative therapeutic digital health technologies. These are specifically designed for dermatology. The aim is to enhance treatment effectiveness. It also seeks to improve accessibility for skin-related conditions. This alliance promises significant advancements in a critical healthcare area.
Samsung Next's investment reinforces technological integration. Sibel Health's ANNE One already uses Samsung mobile devices. This collaboration highlights the potential for future innovations. It creates a differentiated product for healthcare providers. Life science companies also benefit. The system offers clinically validated solutions. It maintains cost-effectiveness. The combined forces aim to expand the reach and impact of medical wearables.
Sibel Health also strengthened its leadership team. Two significant board appointments guide its next growth phase. Kimberly Querrey now serves as Chairwoman of the board. Querrey brings extensive experience. She is Chair and CEO of Gulf Shore Private Capital, LLC. She has been involved with Sibel Health since its 2018 inception. Querrey also serves as a Trustee of Northwestern University. Her leadership provides deep insights into corporate governance and strategic development.
Tim Sullivan joined as a new independent board member. Sullivan is a Co-Founder and Vice Chair of Madison Dearborn Partners. He also chairs the Board of Northwestern Memorial Healthcare Corporation. His background covers innovation, healthcare, and commercial acceleration. Sullivan's expertise will prove invaluable. It will guide Sibel Health's continued expansion and impact. His appointment adds significant strategic depth to the board.
Sibel Health's vision centers on improving patient care. It achieves this through leading-edge technology. Strategic partnerships drive its mission. The company aims to seamlessly integrate continuous health data. This data feeds into clinical trials and everyday clinical care. This transition from reactive monitoring to predictive clinical intelligence is paramount. It allows for proactive interventions.
The company understands care extends beyond hospital walls. Its solutions support this shift. Continuous monitoring enables remote patient management. It provides valuable insights outside traditional healthcare settings. This approach makes healthcare more accessible. It empowers patients and providers alike. Sibel Health champions a future of connected, intelligent health.
Sibel Health maintains its headquarters in Chicago, IL. It also operates an international office in Seoul. This dual presence underscores its global ambitions. The company is poised for significant advancements. Its robust funding, strategic alliances, and strengthened leadership pave the way. Sibel Health continues to define the future of digital health. It drives innovation in medical wearables and AI-driven health analytics.